



Monteris® Medical Press Release

June 1 2014

Monteris Medical's NeuroBlate System for Minimally-Invasive Ablation of Brain Lesions to be Presented at Annual Neurosurgery Meeting

MINNEAPOLIS

Novel Brain Ablation Device Results to be Presented in Washington, D.C.

Monteris Medical announced today that the NeuroBlate® System for MR-guided neurosurgical ablation will be presented to members and attendees at the Biennial meeting of the American Society of Stereotactic and Functional Neurosurgery on June 3 in Washington, D.C. Dr. Gene Barnett, MD, Director of the Rose Ella Burkhardt Brain Tumor and NeuroOncology Center at the Cleveland Clinic, will present his experience utilizing NeuroBlate System laser ablation in patients with brain tumors and radiation necrosis, a chronic inflammatory condition occasionally caused by high-dose, therapeutic radiation. Dr. Barnett and his colleagues have shown that by employing magnetic resonance (MR) imaging and software based visualization offered by the NeuroBlate System they are often able to completely ablate (treat with high heat) tumors through a very small hole in the skull. They published their results in the May issue of the on-line Journal "Cancer Medicine".

"We are pleased to have the NeuroBlate System included in this scientific meeting agenda," remarked John E. Schellhorn, President and CEO of Monteris Medical. "Patients who have received this minimally invasive laser ablation therapy for brain lesions have gone to post-surgical recovery with a small bandage on their scalp rather than a large suture line. We are proud of our technology's contribution to less-invasive brain surgery."

The ASSFN meeting will be held May 31-June 3, 2014 in Washington, D.C.

About the NeuroBlate System®

The NeuroBlate System is FDA-cleared to ablate, necrotize or coagulate soft tissue encountered in the discipline of neurosurgery through the application of thermal therapy. NeuroBlate is a tool, and not a treatment, which is used by physicians to address various medical conditions including brain tumors and tissue inflamed by radiation necrosis, among others. This press release discusses radiation necrosis. NeuroBlate is not indicated to treat, cure, prevent, mitigate or diagnose any specific disease, including radiation necrosis. Full prescribing information for the NeuroBlate System is available at www.monteris.com.

About Monteris®

Monteris Medical is a privately held company developing innovative MRI-guided, laser-based brain lesion therapy. Monteris Medical markets the NeuroBlate® System, a neurosurgical ablation device providing controlled therapy for difficult-to-treat brain lesions. Monteris also offers the AXiiiS® Stereotactic Miniframe; a single use platform for image-guided, stereotactic brain biopsy; and the Atama™ Stabilization System for MRI-guided neurosurgical procedures requiring head fixation. www.monteris.com

Monteris Contact:
John Schellhorn

Phone: 763-253-4710

Email: jschellhorn@monteris.com